Introduction:

In the case titled Mankind Pharma Ltd v. Ram Kumar M/S Dr. Kumars Pharmaceuticals, the Delhi High Court was called upon to decide a dispute surrounding the use of the “Kind” family of marks, a series of well-established trademarks held by Mankind Pharma Limited. Justice Tejas Karia presided over the matter, which revolved around the registration and use of the mark “Unkind” by Ram Kumar, trading as M/S Dr. Kumars Pharmaceuticals. Mankind Pharma Limited, one of India’s leading pharmaceutical companies, asserted that it had established extensive reputation and goodwill in the pharmaceutical sector through continuous use of its distinctive “Kind” family of marks, which included popular names such as “Mankind,” “Lactokind,” “Pregakind,” and others. According to the petitioner, the respondent’s use of the word “Unkind” in connection with pharmaceutical products was not only deceptively similar but also intended to mislead consumers into believing that there existed an association with Mankind Pharma. This, the company argued, was an act of dishonesty that violated the provisions of the Trade Marks Act, 1999, specifically Sections 11 and 57, which protect prior users of marks and permit rectification of the Register of Trade Marks by removing deceptively similar marks. The High Court, after considering the arguments advanced by both sides, ruled in favor of Mankind Pharma Limited, holding that its family of marks deserved a higher level of protection due to their distinctiveness, established reputation, and market recognition. The court directed that the impugned mark “Unkind” be removed from the Register of Trade Marks, thereby reinforcing the principle that trademarks with long-standing usage and association with a particular business deserve strong judicial protection from imitation or exploitation.

Arguments of the Petitioner:

Mankind Pharma Limited, the petitioner, argued that it had been using the “Mankind” mark and the “Kind” family of marks continuously since 1986 through its predecessor in title and had secured multiple trademark registrations protecting the use of these names across pharmaceutical products. The company stressed that the mark “Kind,” though an ordinary English word, had by virtue of extensive and exclusive use, advertising, and sales across decades, acquired a secondary meaning in the pharmaceutical industry and had become uniquely associated with Mankind Pharma’s brand identity. It argued that the “Kind” family of marks had become synonymous with quality, reliability, and trust in healthcare products, and any attempt by third parties to use a deceptively similar suffix or prefix was likely to mislead consumers.

The petitioner submitted that the impugned mark “Unkind” was almost phonetically and visually identical to its registered marks, with the only difference being the prefix “Un,” which was insufficient to distinguish the respondent’s mark from the established family of “Kind” marks. It emphasized that consumers of pharmaceutical products, often being laypersons without specialized knowledge, are highly susceptible to confusion and deception, particularly when the difference in marks is minor. Given the sensitive nature of pharmaceutical products where consumer health and safety are at stake, the petitioner contended that courts must adopt a stricter standard of scrutiny to prevent confusion and protect the consuming public.

The petitioner further alleged that the respondent’s adoption of the mark “Unkind” was not an innocent act but was a dishonest attempt to ride upon the goodwill and reputation of Mankind Pharma. By adopting a mark that mimicked the essential feature of the petitioner’s brand identity, the respondent sought to pass off its goods as being associated with or endorsed by Mankind Pharma, thereby unfairly benefiting from the petitioner’s long-standing reputation. Mankind Pharma thus prayed for cancellation of the impugned mark “Unkind” under Section 57 of the Trade Marks Act, 1999, on the grounds that its presence on the register violated Section 11, which prohibits registration of marks likely to cause confusion with prior registered marks.

Arguments of the Respondent:

On the other hand, the respondent, Ram Kumar trading as M/S Dr. Kumars Pharmaceuticals, defended the registration and use of the mark “Unkind” by contending that the term was sufficiently distinctive and that the addition of the prefix “Un” created a clear difference between its mark and the petitioner’s family of marks. The respondent argued that “Kind” was a common English word that could not be monopolized by a single company and that its use in a trademark did not automatically confer exclusivity unless proven to have acquired distinctiveness. According to the respondent, the petitioner could not claim a blanket right over every mark ending with the word “Kind,” especially when the respondent had coined a new expression with a prefix that altered the overall impression of the mark.

The respondent also submitted that there was no evidence of actual confusion in the marketplace and that the petitioner’s claim of deceptive similarity was speculative rather than substantiated. It argued that the impugned mark had been registered lawfully and had not been challenged for several years, thereby entitling it to protection under the Trade Marks Act. Furthermore, the respondent attempted to highlight that the petitioner’s claim of dishonesty was unfounded, as the choice of the word “Unkind” was arbitrary and not motivated by an intent to exploit Mankind Pharma’s goodwill.

Court’s Judgment:

After carefully examining the submissions of both parties, the Delhi High Court concluded that Mankind Pharma Limited was entitled to higher protection for its “Kind” family of marks. Justice Tejas Karia observed that while the word “Kind” in itself might not be inherently distinctive in the context of pharmaceuticals, its continuous and extensive use by Mankind Pharma since 1986 had conferred upon it a secondary meaning, whereby consumers associated the word “Kind” with the petitioner’s products. The court emphasized that the doctrine of family of marks is well-recognized in trademark law, and where a company has established a series of marks built around a common element, competitors cannot be allowed to appropriate that element to create confusion.

The court found that the impugned mark “Unkind” was deceptively similar to Mankind Pharma’s marks, both phonetically and visually. The addition of the prefix “Un” did not sufficiently distinguish the respondent’s mark, especially in the minds of average consumers who might perceive it as a variant belonging to the petitioner’s family of marks. In pharmaceutical products, the court noted, even minor chances of confusion can have serious consequences, making it imperative to afford stronger protection to established brands.

Justice Karia held that the respondent’s adoption of the impugned mark was dishonest and intended to trade upon the goodwill of Mankind Pharma. The fact that Mankind Pharma was the prior user and registered proprietor of the “Kind” family of marks further tilted the balance in its favor. Accordingly, the court ordered the removal of the impugned mark “Unkind” from the Register of Trade Marks under Section 57 of the Act, holding that its continuation violated Section 11.

The judgment reaffirmed that well-known or extensively used trademarks, even if composed of ordinary words, are entitled to heightened protection under Indian trademark law when they have acquired distinctiveness and consumer recognition. It also underscored the judiciary’s proactive role in ensuring that dishonest adoption of deceptively similar marks does not undermine established goodwill, especially in industries like pharmaceuticals where consumer safety is paramount. By granting Mankind Pharma relief, the court not only safeguarded the petitioner’s proprietary rights but also reinforced the broader public interest in preventing confusion in pharmaceutical markets.